Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    30-October-2000      
Issue 200 Next Update - 14:00 UTC 08:00 EST    31-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Proceed To Article In Today's Vidyya
Leflunomide
Arava (Leflunomide) enhances the treatment of rheumatoid arthritis.


Proceed To Article Treatment Outcomes For Rheumatoid Arthritis Patients Significantly Enhanced By Leflunomide
A landmark study highlighted Sunday during a press conference at the 64th Annual American College of Rheumatology (ACR) Annual Meeting in Philadelphia showed that twice as many patients taking leflunomide experienced significant benefit from the rheumatoid arthritis (RA) therapy, compared to the control group. More...

Proceed To Article Prescribing Information - Arava (Leflunomide)
When introduced in 1998, leflunomide, an oral disease-modifying antirheumatic drug (DMARD), was the first new treatment for RA in more than a decade. It has been shown to retard structural damage and reduce signs and symptoms in all stages and severities of RA. Get the full prescribing information in today's Vidyya. More...

Proceed To Article Enbrel® (Etanercept) Long-Term Clinical Trial Data Presented At The American College of Rheumatology Annual Meeting
Patients with moderately to severely active rheumatoid arthritis experienced sustained reduction of joint pain and swelling for as long as four years of treatment with Enbrel(R) (etanercept), according to results from a long-term open-label study. Interim results of this on going study are being presented at the 64th Annual Scientific Meeting of the American College of Rheumatology by Dr. Larry Moreland of the University of Alabama at Birmingham. More...

Proceed To Article Prescribing Information - Enbrel (Enteracept)
The U.S. Food and Drug Administration (FDA) has approved Enbrel as a first-line treatment of moderately to severely active rheumatoid arthritis. Enbrel is indicated for reducing signs and symptoms and delaying structural damage in patients with moderately to severely active rheumatoid arthritis. Get the full prescribing information in today's issue.More...

Proceed To Article

Information For Patients - Rheumatoid Arthritis
This educational handout is for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease. The educational handout describes how rheumatoid arthritis develops, how it is diagnosed, and how it is treated, including what patients can do to help manage their disease. More...


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.